Pozen MT-100 Migraine Combo Goes To Advisory Committee August 4
This article was originally published in The Pink Sheet Daily
Executive Summary
Tardive dyskinesia and cardiovascular issues are likely discussion topics for FDA’s Peripheral & Central Nervous System Drugs Advisory Committe. Treatment was to be reviewed by the committee in May but was postponed due to “scheduling conflicts.”